EC chi hơn 70 triệu USD mua thuốc remdesivir điều trị COVID-19

(TTXVN/Vietnam+) 08:49 30/07/2020

Nhằm đáp ứng nhu cầu cấp bách hiện nay cho các bệnh nhân mắc dịch viêm đường hô hấp cấp COVID-19 ở châu Âu, ngày 29/7, Ủy ban châu Âu (EC) thông báo đã đồng ý mua thuốc kháng virus remdesivir vốn khan hiếm của công ty dược phẩm Mỹ Gilead Sciences.

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